ORTHOPEDIATRICS CORP Revenue From Contract With Customer Excluding Assessed Tax

• ORTHOPEDIATRICS CORP showed an increase of +15.4% in Revenue From Contract With Customer Excluding Assessed Tax from 2024 to 2025.
• This data is from ORTHOPEDIATRICS CORP's annual report (Form 10-K), filed with the SEC on March 4, 2026.
• XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Quarterly values from 10-Q filings: Q1 2017: $9.76 million | Q2 2017: $11.80 million | Q3 2017: $12.38 million | Q4 2017: $11.68 million | Q1 2018: $12.09 million | Q2 2018: $15.08 million | Q3 2018: $15.82 million | Q4 2018: $14.57 million | Q1 2019: $14.66 million | Q2 2019: $18.20 million | Q3 2019: $20.74 million | Q4 2019: $18.95 million | Q1 2020: $16.36 million | Q2 2020: $13.59 million | Q3 2020: $22.21 million | Q4 2020: $18.92 million | Q1 2021: $21.46 million | Q2 2021: $26.70 million | Q3 2021: $25.08 million | Q4 2021: $24.81 million | Q1 2022: $23.42 million | Q2 2022: $32.93 million | Q3 2022: $34.95 million | Q1 2023: $31.59 million | Q2 2023: $39.56 million | Q3 2023: $39.97 million | Q1 2024: $44.69 million | Q2 2024: $52.80 million | Q3 2024: $54.57 million | Q1 2025: $52.41 million | Q2 2025: $61.08 million | Q3 2025: $61.25 million.
• Over the full 10 years of available data (2016 to 2025), ORTHOPEDIATRICS CORP's Revenue From Contract With Customer Excluding Assessed Tax has grown by 533.7%.
• Historical annual values: Fiscal year 2025: $236.35 million | Fiscal year 2024: $204.73 million | Fiscal year 2023: $148.73 million | Fiscal year 2022: $122.29 million | Fiscal year 2021: $98.05 million | Fiscal year 2020: $71.08 million | Fiscal year 2019: $72.55 million | Fiscal year 2018: $57.56 million | Fiscal year 2017: $45.62 million | Fiscal year 2016: $37.30 million.
• Data sourced from SEC EDGAR public filings as of August 9, 2026.

Last verified: August 9, 2026